MX2010009576A - Derivados de quinoxalinona como estimulantes de la secrecion de insulina, metodos para obtenerlos y su uso en el tratamiento de la diabetes. - Google Patents

Derivados de quinoxalinona como estimulantes de la secrecion de insulina, metodos para obtenerlos y su uso en el tratamiento de la diabetes.

Info

Publication number
MX2010009576A
MX2010009576A MX2010009576A MX2010009576A MX2010009576A MX 2010009576 A MX2010009576 A MX 2010009576A MX 2010009576 A MX2010009576 A MX 2010009576A MX 2010009576 A MX2010009576 A MX 2010009576A MX 2010009576 A MX2010009576 A MX 2010009576A
Authority
MX
Mexico
Prior art keywords
diabetes
treatment
insulin secretion
obtaining
methods
Prior art date
Application number
MX2010009576A
Other languages
English (en)
Inventor
Micheline Kergoat
Gerard Botton
Samer Elbawab
Christine Charon
Eric Valerur
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MX2010009576A publication Critical patent/MX2010009576A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se relaciona con nuevos derivados de quinoxalinona de la fórmula (I), en donde R1, R2, R3, R4, R5 y R6 son como se definen en la reivindicación 1, como estimuladores de la secreción de insulina. La invención también se relaciona con la preparación y uso de estos derivados de quinoxalinona para la profilaxis y/o tratamiento de diabetes y las patologías asociadas. Otros compuestos preferidos son los compuestos de la fórmula general (I), en donde R1, R2, R3, R4, R5 y R6 pueden sustituirse opcionalmente por uno o más grupos seleccionados de Z. (ver fórmula (I)).
MX2010009576A 2008-03-05 2009-01-15 Derivados de quinoxalinona como estimulantes de la secrecion de insulina, metodos para obtenerlos y su uso en el tratamiento de la diabetes. MX2010009576A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08004053 2008-03-05
PCT/EP2009/000209 WO2009109258A1 (en) 2008-03-05 2009-01-15 Quinoxalinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes

Publications (1)

Publication Number Publication Date
MX2010009576A true MX2010009576A (es) 2010-09-24

Family

ID=40547943

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010009576A MX2010009576A (es) 2008-03-05 2009-01-15 Derivados de quinoxalinona como estimulantes de la secrecion de insulina, metodos para obtenerlos y su uso en el tratamiento de la diabetes.

Country Status (18)

Country Link
US (2) US8415352B2 (es)
EP (1) EP2247580B1 (es)
JP (1) JP5618837B2 (es)
KR (1) KR101637387B1 (es)
CN (1) CN101952258B (es)
AR (1) AR070797A1 (es)
AU (1) AU2009221327B2 (es)
BR (1) BRPI0908406B8 (es)
CA (1) CA2717718C (es)
DK (1) DK2247580T3 (es)
EA (1) EA021904B1 (es)
ES (1) ES2548583T3 (es)
HU (1) HUE027811T2 (es)
IL (1) IL207720A (es)
MX (1) MX2010009576A (es)
PT (1) PT2247580E (es)
WO (1) WO2009109258A1 (es)
ZA (1) ZA201007059B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
RS58043B1 (sr) 2012-04-24 2019-02-28 Vertex Pharma Inhibitori dna-pk
EP3527563B1 (en) 2013-03-12 2021-09-01 Vertex Pharmaceuticals Incorporated Dna-pk inhibitors
SG11201602962PA (en) 2013-10-17 2016-05-30 Vertex Pharma Co-crystals of (s)-n-methyl-8-(1-((2'-methyl-[4,5'-bipyrimidin]-6-yl)amino)propan-2-yl)quinoline-4-carboxamide and deuterated derivatives thereof as dna-pk inhibitors
CN104628661A (zh) * 2015-02-05 2015-05-20 北京理工大学 一类喹喔啉酮衍生物作为醛糖还原酶抑制剂的结构、制备方法及用途
PT3394083T (pt) 2015-12-24 2021-12-07 Univ California Derivados de n-[5-[(3,4-dimetoxifenil)metil]-1,3,4-tiadiazol-2-il]-2-metoxi-benzenoacetamida e compostos relacionados como ativadores de cftr para tratar a obstipação ou colestase
PT3394046T (pt) * 2015-12-24 2022-04-05 Univ California Reguladores de cftr e seus métodos de uso
WO2017112951A1 (en) 2015-12-24 2017-06-29 The Regents Of The University Of California Cftr regulators and methods of use thereof
CN105769870A (zh) * 2016-04-09 2016-07-20 李曼 一种治疗糖尿病的药物
RU2758669C2 (ru) 2016-09-27 2021-11-01 Вертекс Фармасьютикалз Инкорпорейтед Способ лечения рака с применением сочетания днк-поражающих агентов и ингибиторов днк-пк
CA3073718A1 (en) 2017-08-24 2019-02-28 The Regents Of The University Of California Ocular pharmaceutical compositions
CN109793739A (zh) * 2019-01-14 2019-05-24 北京理工大学 一种喹喔啉酮衍生物的结构、制备方法及用途
CN109796417A (zh) * 2019-01-14 2019-05-24 北京理工大学 一系列喹喔啉酮衍生物的结构、制备方法及用途
CN114907323B (zh) * 2022-05-31 2023-08-15 内蒙古民族大学 喹喔啉酮类化合物及其制备方法和应用
CN114957222B (zh) * 2022-05-31 2023-08-15 内蒙古民族大学 化合物及其制备方法和用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU410015A1 (es) * 1971-06-22 1974-01-05
SU616955A1 (ru) * 1977-03-02 2006-12-27 Пермский ордена Трудового Красного Знамени государственный университет им.А.М.Горького 2-(α-бромфенацил)-хиноксалон-3, проявляющий противовоспалительную активность
US4181724A (en) * 1978-09-11 1980-01-01 The Upjohn Company Quinoxalinone compounds useful for expanding the lumina or air passages in mammals
FR2653430B1 (fr) * 1989-10-23 1991-12-20 Pf Medicament Nouveaux derives de dihydro-1,2 oxo-2 quinoxalines, leur preparation et leur application en therapeutique.
US6348474B1 (en) 1997-06-27 2002-02-19 Fujisawa Pharmaceutical Co., Ltd. Sulfonamide compounds and medicinal use thereof
DE69824025T2 (de) * 1997-09-01 2005-06-16 Kyorin Pharmaceutical Co., Ltd. 6,7-asymmetrisch disubstituierte chinoxalincarbonsäurederivate, additionssalze davon und verfahren zur herstellung von beiden
WO1999050254A1 (en) 1998-03-31 1999-10-07 Warner-Lambert Company Quinoxalinones as serine protease inhibitors such as factor xa and thrombin
DE10343098A1 (de) * 2003-09-18 2005-04-14 Bayer Healthcare Ag Tetrahydrochinoxaline und ihre Verwendung
DE602004007693T2 (de) * 2004-01-06 2008-06-05 Janssen Pharmaceutica N.V. (3-oxo-3,4-dihydro-chinoxalin-2-yl-amino)-benzamid-derivate und verwandte verbindungen als glykogen-phosphorylase-hemmer zur behandlung von diabetes und adipositas
DE102004023332A1 (de) * 2004-05-12 2006-01-19 Bayer Cropscience Gmbh Chinoxalin-2-on-derivate, diese enthaltende nutzpflanzenschützende Mittel und Verfahren zu ihrer Herstellung und deren Verwendung
WO2007135527A2 (en) * 2006-05-23 2007-11-29 Pfizer Products Inc. Benzimidazolyl compounds

Also Published As

Publication number Publication date
AR070797A1 (es) 2010-05-05
IL207720A (en) 2014-12-31
DK2247580T3 (en) 2015-10-05
US20110015194A1 (en) 2011-01-20
ZA201007059B (en) 2011-06-29
CA2717718A1 (en) 2009-09-11
EP2247580A1 (en) 2010-11-10
US8835634B2 (en) 2014-09-16
EP2247580B1 (en) 2015-07-08
WO2009109258A1 (en) 2009-09-11
JP5618837B2 (ja) 2014-11-05
ES2548583T3 (es) 2015-10-19
CN101952258B (zh) 2014-03-19
CA2717718C (en) 2016-05-31
PT2247580E (pt) 2015-10-19
BRPI0908406B8 (pt) 2023-02-07
US8415352B2 (en) 2013-04-09
HUE027811T2 (en) 2016-11-28
KR101637387B1 (ko) 2016-07-07
JP2011513343A (ja) 2011-04-28
BRPI0908406B1 (pt) 2019-04-09
EA021904B1 (ru) 2015-09-30
EA201001407A1 (ru) 2011-06-30
KR20100123899A (ko) 2010-11-25
BRPI0908406A2 (pt) 2015-08-11
AU2009221327B2 (en) 2014-03-27
IL207720A0 (en) 2010-12-30
CN101952258A (zh) 2011-01-19
US20130123257A1 (en) 2013-05-16
AU2009221327A1 (en) 2009-09-11

Similar Documents

Publication Publication Date Title
MX2010009576A (es) Derivados de quinoxalinona como estimulantes de la secrecion de insulina, metodos para obtenerlos y su uso en el tratamiento de la diabetes.
TW200745004A (en) Novel compounds, their preparation and use
GEP20146125B (en) Aminopyrimidines as syk inhibitors
MX2011011661A (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750.
IN2012DN01233A (es)
TN2011000259A1 (en) Substituted pyrimidines for the treatment of diseases such as cancer
MY149648A (en) Carboxylalkylene-phenyl)-phenyl-oxalamides, method for the production thereof, and use of same as a medicament
TW200621262A (en) New dihydropteridione derivatives, process for their manufacture and their use as medicament
TW201129565A (en) Tricyclic heterocyclic compounds, compositions and methods of use thereof
TN2011000279A1 (en) Novel pyrazole -4-n-alkoxycarboxamides as microbiocides
GEP20146102B (en) Compounds and compositions as protein kinase inhibitors
UA83875C2 (ru) Производные хинолина для применения в качестве микобактериальных ингибиторов
TW200621777A (en) New dihydropteridione derivatives, process for their manufacture and their use as medicament
PT1902037E (pt) 2,4-diamino-pirimidinas como inibidores de aurora
TN2012000249A1 (en) Pyrazine derivatives and their use in the treatment of neurological disorders
MX2010009022A (es) Derivados 16 alfa, 17 alfa-acetal glucocorticoesteroideos y su uso.
EP2571876A4 (en) SUBSTITUTED SEVEN-HETEROCYCLIC COMPOUNDS AS DIPEPTIDYL-PEPTIDASE IV INHIBITORS FOR THE TREATMENT OF DIABETES
MY155695A (en) Quinoxalinedione derivatives
MX2010009922A (es) Activadores de piridazinona glucocinasa.
MX2010009575A (es) Derivados de pirazinonas como estimulantes de la secrecion de insulina, metodos para obtenerlos y su uso en el tratamiento de la diabetes.
MX2010005649A (es) Compuestos novedosos como ligandos del receptor canabinoide y sus usos.
NZ746950A (en) Heterocyclic gpr119 agonist compounds
MX2009007713A (es) Derivados de piridazina, procedimientos para su preparacion y su uso como fungicidas.
JO2682B1 (en) Derivatives of alkynil-8.1-naphthayridone, preparations thereof and therapeutic use thereof
MA32505B1 (fr) 5-alcynyl-pyrimidines

Legal Events

Date Code Title Description
FG Grant or registration